|
1
|
Bianchi G and Munshi NC: Pathogenesis
beyond the cancer clone(s) in multiple myeloma. Blood.
125:3049–3058. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abe M: Targeting the interplay between
myeloma cells and the bone marrow microenvironment in myeloma. Int
J Hematol. 94:334–343. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Meads MB, Hazlehurst LA and Dalton WS: The
bone marrow microenvironment as a tumor sanctuary and contributor
to drug resistance. Clin Cancer Res. 14:2519–2526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Furukawa Y and Kikuchi J: Molecular
pathogenesis of multiple myeloma. Int J Clin Oncol. 20:413–422.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harmer D, Falank C and Reagan MR:
Interleukin-6 interweaves the bone marrow microenvironment, bone
loss, and multiple myeloma. Front Endocrinol (Lausanne). 9:7882019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Choudhury SR, Ashby C, Tytarenko R, Bauer
M, Wang Y, Deshpande S, Den J, Schinke C, Zangari M, Thanendrarajan
S, et al: The functional epigenetic landscape of aberrant gene
expression in molecular subgroups of newly diagnosed multiple
myeloma. J Hematol Oncol. 13:1082020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heuck CJ, Mehta J, Bhagat T, Gundabolu K,
Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, et
al: Myeloma is characterized by stage-specific alterations in DNA
methylation that occur early during myelomagenesis. J Immunol.
190:2966–2975. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Walker BA, Wardell CP, Chiecchio L, Smith
EM, Boyd KD, Neri A, Davies FE, Ross FM and Morgan GJ: Aberrant
global methylation patterns affect the molecular pathogenesis and
prognosis of multiple myeloma. Blood. 117:553–562. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maes K, De Smedt E, Lemaire M, De Raeve H,
Menu E, Van Valckenborgh E, McClue S, Vanderkerken K and De Bruyne
E: The role of DNA damage and repair in decitabine-mediated
apoptosis in multiple myeloma. Oncotarget. 5:3115–3129. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kiziltepe T, Hideshima T, Catley L, Raje
N, Yasui H, Shiraishi N, Okawa Y, Ikeda H, Vallet S, Pozzi S, et
al: 5-Azacytidine, a DNA methyltransferase inhibitor, induces
ATR-mediated DNA double-strand break responses, apoptosis, and
synergistic cytotoxicity with doxorubicin and bortezomib against
multiple myeloma cells. Mol Cancer Ther. 6:1718–1727. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carew JS, Giles FJ and Nawrocki ST:
Histone deacetylase inhibitors: Mechanisms of cell death and
promise in combination cancer therapy. Cancer Lett. 269:7–17. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bolden JE, Peart MJ and Johnstone RW:
Anticancer activities of histone deacetylase inhibitors. Nat Rev
Drug Discov. 5:769–784. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC
and Huang DP: Frequent hypermethylation of p16 and p15 genes in
multiple myeloma. Blood. 89:2500–2506. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wong IH, Ng MH, Lee JC, Lo KW, Chung YF
and Huang DP: Transcriptional silencing of the p16 gene in human
myeloma-derived cell lines by hypermethylation. Br J Haematol.
103:168–175. 1998.PubMed/NCBI
|
|
15
|
Zhang XD, Gillespie SK, Borrow JM and
Hersey P: The histone deacetylase inhibitor suberic bishydroxamate
regulates the expression of multiple apoptotic mediators and
induces mitochondria-dependent apoptosis of melanoma cells. Mol
Cancer Ther. 3:425–435. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gillespie S, Borrow J, Zhang XD and Hersey
P: Bim plays a crucial role in synergistic induction of apoptosis
by the histone deacetylase inhibitor SBHA and TRAIL in melanoma
cells. Apoptosis. 11:2251–2265. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Elmallah MIY and Micheau O: Epigenetic
regulation of TRAIL signaling: Implication for cancer therapy.
Cancers (Basel). 11:8502019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen J, Hong Z, Zhao C, Bi Q and Qiu B:
Associations between polymorphisms of the PDLIM4 gene and
susceptibility to osteoporotic fracture in an elderly population of
Han Chinese. Biosci Rep. 39:BSR201815052019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kadrmas JL and Beckerle MC: The LIM
domain: From the cytoskeleton to the nucleus. Nat Rev Mol Cell
Biol. 5:920–931. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ono R, Kaisho T and Tanaka T: PDLIM1
inhibits NF-κB-mediated inflammatory signaling by sequestering the
p65 subunit of NF-κB in the cytoplasm. Sci Rep. 5:183272015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kravchenko DS, Ivanova AE, Podshivalova ES
and Chumakov SP: PDLIM4/RIL-mediated regulation of Src and
malignant properties of breast cancer cells. Oncotarget. 11:22–30.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Y, Qian J, Lin J, Qian W, Yang J, Chai
HY, Wang CZ, Deng ZQ, Yao DM, Chen Q and Ma JC: Reduced expression
of PDLIM4 gene correlates with good prognosis in acute myeloid
leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 21:1111–1115.
2013.PubMed/NCBI
|
|
23
|
Vanaja DK, Ballman KV, Morlan BW, Cheville
JC, Neumann RM, Lieber MM, Tindall DJ and Young CY: PDLIM4
repression by hypermethylation as a potential biomarker for
prostate cancer. Clin Cancer Res. 12:1128–1136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Boumber YA, Kondo Y, Chen X, Shen L,
Gharibyan V, Konishi K, Estey E, Kantarjian H, Garcia-Manero G and
Issa JP: RIL, a LIM gene on 5q31, is silenced by methylation in
cancer and sensitizes cancer cells to apoptosis. Cancer Res.
67:1997–2005. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fernando RC, de Carvalho F, Mazzotti DR,
Evangelista AF, Braga WMT, de Lourdes Chauffaille M, Leme AFP and
Colleoni GWB: Multiple myeloma cell lines and primary tumors
proteoma: Protein biosynthesis and immune system as potential
therapeutic targets. Genes Cancer. 6:462–471. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lodé L, Eveillard M, Trichet V, Soussi T,
Wuillème S, Richebourg S, Magrangeas F, Ifrah N, Campion L, Traullé
C, et al: Mutations in TP53 are exclusively associated with
del(17p) in multiple myeloma. Haematologica. 95:1973–1976. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wei B, Yang S, Zhang B and Feng Y:
Clinicopathological significance of p15 promoter hypermethylation
in multiple myeloma: A meta-analysis. Onco Targets Ther.
9:4015–4022. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li J, Bi L, Lin Y, Lu Z and Hou G:
Clinicopathological significance and potential drug target of
p15INK4B in multiple myeloma. Drug Des Devel Ther. 8:2129–2136.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nguen DH, Zhou T, Shu J and Mao JH:
Quantifying chromogen intensity in immunohistochemistry via
reciprocal intensity. Cancer InCytes. 2:1–4. 2013.
|
|
30
|
Ingersoll SB, Thoni ND, Ahmed F, Monahan
KA, Caballero L, Batista A, Ahmad S and Edwards JR: Role of the
IL-6 pathway to multiple myeloma cell growth and its implications
in target gene hypermethylation. Blood. 110:47692007. View Article : Google Scholar
|
|
31
|
Ingersoll SB, Ahmad S, Thoni ND, Ahmed FH,
Monahan KA and Edwards JR: Targeting the IL-6 pathway in multiple
myeloma and its implications in cancer-associated gene
hypermethylation. Med Chem. 7:473–479. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hodge DR, Li D, Qi SM and Farrar WL: IL-6
induces expression of the Fli-1 proto-oncogene via STAT3. Biochem
Biophys Res Commun. 292:287–291. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hodge DR, Peng B, Cherry JC, Hurt EM, Fox
SD, Kelley JA, Munroe DJ and Farrar WL: Interleukin 6 supports the
maintenance of p53 tumor suppressor gene promoter methylation.
Cancer Res. 65:4673–4682. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Oka M, Meacham AM, Hamazaki T, Rodić N,
Chang LJ and Terada N: De novo DNA methyltransferases Dnmt3a and
Dnmt3b primarily mediate the cytotoxic effect of
5-aza-2′-deoxycytidine. Oncogene. 24:3091–3099. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fu HY, Shen JZ, Wu Y, Shen SF, Zhou HR and
Fan LP: Arsenic trioxide inhibits DNA methyltransferase and
restores expression of methylation-silenced CDKN2B/CDKN2A genes in
human hematologic malignant cells. Oncol Rep. 24:335–343.
2010.PubMed/NCBI
|
|
36
|
Tessoulin B, Moreau-Aubry A, Descamps G,
Gomez-Bougie P, Maïga S, Gaignard A, Chiron D, Ménoret E, Le Gouill
S, Moreau P, et al: Whole-exon sequencing of human myeloma cell
lines shows mutations related to myeloma patients at relapse with
major hits in the DNA regulation and repair pathways. J Hematol
Oncol. 11:1372018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Moreaux J, Klein B, Bataille R, Descamps
G, Maïga S, Hose D, Goldschmidt H, Jauch A, Rème T, Jourdan M, et
al: A high-risk signature for patients with multiple myeloma
established from the molecular classification of human myeloma cell
lines. Haematologica. 96:574–582. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Manier S, Salem KZ, Park J, Landau DA,
Getz G and Ghobrial IM: Genomic complexity of multiple myeloma and
its clinical implications. Nat Rev Clin Oncol. 14:100–113. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pawlyn C, Kaiser MF, Heuck C, Melchor L,
Wardell CP, Murison A, Chavan SS, Johnson DC, Begum DB, Dahir NM,
et al: The spectrum and clinical impact of epigenetic modifier
mutations in myeloma. Clin Cancer Res. 22:5783–5794. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Caprio C, Sacco A, Giustini V and Roccaro
AM: Epigenetic aberrations in multiple myeloma. Cancers (Basel).
12:29962020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang XG, Gaillard JP, Robillard N, Lu ZY,
Gu ZJ, Jourdan M, Boiron JM, Bataille R and Klein B: Reproducible
obtaining of human myeloma cell lines as a model for tumor stem
cell study in human multiple myeloma. Blood. 83:3654–3663. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fabris S, Agnelli L, Mattioli M, Baldini
L, Ronchetti D, Morabito F, Verdelli D, Nobili L, Intini D, Callea
V, et al: Characterization of oncogene dysregulation in multiple
myeloma by combined FISH and DNA microarray analyses. Genes
Chromosomes Cancer. 42:117–127. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhan F, Hardin J, Kordsmeier B, Bumm K,
Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, et al:
Global gene expression profiling of multiple myeloma, monoclonal
gammopathy of undetermined significance, and normal bone marrow
plasma cells. Blood. 99:1745–1757. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Claus R and Lübbert M: Epigenetic targets
in hematopoietic malignancies. Oncogene. 22:6489–6496. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nan X, Cross S and Bird A: Gene silencing
by methyl-CpG-binding proteins. Novartis Found Symp. 214:6–21.
46–50. 1998.PubMed/NCBI
|
|
46
|
Theoleyre S, Wittrant Y, Tat SK, Fortun Y,
Redini F and Heymann D: The molecular triad OPG/RANK/RANKL:
Involvement in the orchestration of pathophysiological bone
remodeling. Cytokine Growth Factor Rev. 15:457–475. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Burger R, Günther A, Klausz K, Staudinger
M, Peipp M, Penas EM, Rose-John S, Wijdenes J and Gramatzki M: Due
to interleukin-6 type cytokine redundancy only glycoprotein 130
receptor blockade efficiently inhibits myeloma growth.
Haematologica. 102:381–390. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Heinrich PC, Behrmann I, Haan S, Hermanns
HM, Müller-Newen G and Schaper F: Principles of interleukin
(IL)-6-type cytokine signalling and its regulation. Biochem J.
374:1–20. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chipoy C, Berreur M, Couillaud S, Pradal
G, Vallette F, Colombeix C, Rédini F, Heymann D and Blanchard F:
Downregulation of osteoblast markers and induction of the glial
fibrillary acidic protein by oncostatin M in osteosarcoma cells
require PKCdelta and STAT3. J Bone Miner Res. 19:1850–1861. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Blanchard F, Duplomb L, Baud'huin M and
Brounais B: The dual role of IL-6-type cytokines on bone remodeling
and bone tumors. Cytokine Growth Factor Rev. 20:19–28. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bellido T, O'Brien CA, Roberson PK and
Manolagas SC: Transcriptional activation of the p21(WAF1,CIP1,SDI1)
gene by interleukin-6 type cytokines. A prerequisite for their
pro-differentiating and anti-apoptotic effects on human
osteoblastic cells. J Biol Chem. 273:21137–21144. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jilka RL, Weinstein RS, Bellido T, Parfitt
AM and Manolagas SC: Osteoblast programmed cell death (apoptosis):
Modulation by growth factors and cytokines. J Bone Miner Res.
13:793–802. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hollenbach PW, Nguyen AN, Brady H,
Williams M, Ning Y, Richard N, Krushel L, Aukerman SL, Heise C and
MacBeth KJ: A comparison of azacitidine and decitabine activities
in acute myeloid leukemia cell lines. PLoS One. 5:e90012010.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Maes K, Menu E, Van Valckenborgh E, Van
Riet I, Vanderkerken K and De Bruyne E: Epigenetic modulating
agents as a new therapeutic approach in multiple myeloma. Cancers
(Basel). 5:430–461. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Schmelz K, Sattler N, Wagner M, Lübbert M,
Dörken B and Tamm I: Induction of gene expression by
5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and
myelodysplastic syndrome (MDS) but not epithelial cells by
DNA-methylation-dependent and -independent mechanisms. Leukemia.
19:103–111. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ocker M and Schneider-Stock R: Histone
deacetylase inhibitors: Signalling towards p21cip1/waf1. Int J
Biochem Cell Biol. 39:1367–1374. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lagger G, Doetzlhofer A, Schuettengruber
B, Haidweger E, Simboeck E, Tischler J, Chiocca S, Suske G,
Rotheneder H, Wintersberger E and Seiser C: The tumor suppressor
p53 and histone deacetylase 1 are antagonistic regulators of the
cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol Cell
Biol. 23:2669–2679. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Richon VM, Sandhoff TW, Rifkind RA and
Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1
expression and gene-associated histone acetylation. Proc Natl Acad
Sci USA. 97:10014–10019. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Li J, Zheng X, Gao M, Zhao J, Li Y, Meng
X, Qian B and Li J: Suberoyl bis-hydroxamic acid activates Notch1
signaling and induces apoptosis in anaplastic thyroid carcinoma
through p53. Oncol Rep. 37:458–464. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wang X, Zhu YB, Cui HP and Yu TT: Aberrant
promoter methylation of p15 (INK4b) and p16 (INK4a) genes may
contribute to the pathogenesis of multiple myeloma: A
meta-analysis. Tumour Biol. 35:9035–9043. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Stanganelli C, Arbelbide J, Fantl DB,
Corrado C and Slavutsky I: DNA methylation analysis of tumor
suppressor genes in monoclonal gammopathy of undetermined
significance. Ann Hematol. 89:191–199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Luzna P, Flodrova P, Janovska L,
Zapletalova J, Minarik J, Kolar Z and Trtkova KS: Different gene
methylation status of the CDKN2B and/or PDLIM4 as the result of
comparative analysis to the global DNA methylation in unsorted cell
population of multiple myeloma patients. Ann Hematol Oncol.
6:12572019.
|
|
63
|
Yuregir OO, Yurtcu E, Kizilkilic E, Kocer
NE, Ozdogu H and Sahin FI: Detecting methylation patterns of p16,
MGMT, DAPK and E-cadherin genes in multiple myeloma patients. Int J
Lab Hematol. 32:142–149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Gonzalez-Paz N, Chng WJ, McClure RF, Blood
E, Oken MM, Van Ness B, James CD, Kurtin PJ, Henderson K, Ahmann
GJ, et al: Tumor suppressor p16 methylation in multiple myeloma:
Biological and clinical implications. Blood. 109:1228–1232. 2007.
View Article : Google Scholar : PubMed/NCBI
|
